Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress
Tourmaline Bio (NASDAQ: TRML) has announced its plans to present two posters at the 19th Annual Cardiometabolic Health Congress (CMHC) in Boston, MA, from October 17-19, 2024. The presentations highlight the company's commitment to understanding inflammatory cardiovascular risk and potential therapeutic mechanisms of IL-6 inhibition.
The first poster, titled 'Utilization of High-Sensitivity C-Reactive Protein Testing in Primary and Secondary ASCVD Prevention', involves collaborations with Atropos Health and Wake Forest University School of Medicine. The second poster, 'Effect of IL-6 Inhibition on Lipoprotein(a) Levels: A Systematic Review and Meta-Analysis', is a joint effort with Wake Forest University School of Medicine and an independent researcher from Toronto.
These presentations underscore Tourmaline Bio's focus on developing transformative medicines for patients with life-altering immune and inflammatory diseases.
Tourmaline Bio (NASDAQ: TRML) ha annunciato i suoi piani per presentare due poster al 19° Congresso Annuale sulla Salute Cardiometabolica (CMHC) a Boston, MA, dal 17 al 19 ottobre 2024. Le presentazioni evidenziano l'impegno dell'azienda nella comprensione del rischio cardiovascolare infiammatorio e dei potenziali meccanismi terapeutici dell'inibizione di IL-6.
Il primo poster, dal titolo 'Utilizzo del Test della Proteina C-Reattiva ad Alta Sensibilità nella Prevenzione Primaria e Secondaria dell'ASCVD', coinvolge collaborazioni con Atropos Health e la Wake Forest University School of Medicine. Il secondo poster, 'Effetto dell'Inibizione di IL-6 sui Livelli di Lipoproteina(a): Una Revisione Sistematica e Meta-Analisi', è un'iniziativa congiunta con la Wake Forest University School of Medicine e un ricercatore indipendente di Toronto.
Queste presentazioni sottolineano il focus di Tourmaline Bio nello sviluppo di medicinali trasformativi per pazienti con malattie autoimmuni e infiammatorie che alterano la vita.
Tourmaline Bio (NASDAQ: TRML) ha anunciado sus planes para presentar dos carteles en el 19° Congreso Anual de Salud Cardiometabólica (CMHC) en Boston, MA, del 17 al 19 de octubre de 2024. Las presentaciones resaltan el compromiso de la empresa con la comprensión del riesgo cardiovascular inflamatorio y los posibles mecanismos terapéuticos de la inhibición de IL-6.
El primer cartel, titulado 'Utilización de Pruebas de Proteína C Reactiva de Alta Sensibilidad en la Prevención Primaria y Secundaria de ASCVD', involucra colaboraciones con Atropos Health y la Escuela de Medicina de la Universidad de Wake Forest. El segundo cartel, 'Efecto de la Inhibición de IL-6 sobre los Niveles de Lipoproteína(a): Una Revisión Sistemática y Meta-Análisis', es un esfuerzo conjunto con la Escuela de Medicina de la Universidad de Wake Forest y un investigador independiente de Toronto.
Estas presentaciones subrayan el enfoque de Tourmaline Bio en el desarrollo de medicamentos transformadores para pacientes con enfermedades inmunitarias e inflamatorias que alteran la vida.
투말린 바이오 (NASDAQ: TRML)는 2024년 10월 17일부터 19일까지 매사추세츠주 보스턴에서 열리는 제19회 심혈관 대사 건강 학회(CMHC)에서 두 개의 포스터를 발표할 계획을 발표했습니다. 이러한 발표는 염증성 심혈관 위험과 IL-6 억제의 잠재적 치료 메커니즘을 이해하려는 회사의 헌신을 강조합니다.
첫 번째 포스터는 '일차 및 이차 ASCVD 예방에서 고감도 C-반응성 단백질 검사 활용'라는 제목을 가지고 있으며, Atropos Health 및 웨이크 포레스트 대학 의과대학과 협력하여 진행됩니다. 두 번째 포스터 'IL-6 억제가 리포프로테인(a) 수치에 미치는 영향: 체계적 검토 및 메타 분석'은 웨이크 포레스트 대학 의과대학 및 토론토의 독립 연구자와 공동으로 진행됩니다.
이러한 발표는 삶을 변화시키는 면역 및 염증 질환을 앓고 있는 환자를 위한 혁신적인 의약품 개발에 대한 투말린 바이오의 초점을 강조합니다.
Tourmaline Bio (NASDAQ: TRML) a annoncé ses projets de présenter deux affiches lors du 19e Congrès Annuel sur la Santé Cardiovasculaire Métabolique (CMHC) à Boston, MA, du 17 au 19 octobre 2024. Les présentations soulignent l'engagement de l'entreprise à comprendre le risque cardiovasculaire inflammatoire et les mécanismes thérapeutiques potentiels de l'inhibition de l'IL-6.
La première affiche, intitulée 'Utilisation des Tests de Protéine C-Réactive à Haute Sensibilité dans la Prévention Primaire et Secondaire de l'ASCVD', implique des collaborations avec Atropos Health et l'École de Médecine de l'Université de Wake Forest. La deuxième affiche, 'Effet de l'Inhibition de l'IL-6 sur les Niveaux de Lipoprotéine(a) : une Revue Systématique et une Méta-Analyse', est un effort commun avec l'École de Médecine de l'Université de Wake Forest et un chercheur indépendant de Toronto.
Ces présentations soulignent l'accent mis par Tourmaline Bio sur le développement de médicaments transformateurs pour les patients souffrant de maladies immunitaires et inflammatoires changeant la vie.
Tourmaline Bio (NASDAQ: TRML) hat seine Pläne angekündigt, zwei Poster auf dem 19. Jahrestreffen der kardiometabolischen Gesundheit (CMHC) in Boston, MA, vom 17. bis 19. Oktober 2024 zu präsentieren. Die Präsentationen heben das Engagement des Unternehmens hervor, das entzündliche kardiovaskuläre Risiko und die potenziellen therapeutischen Mechanismen der IL-6-Inhibition zu verstehen.
Das erste Poster mit dem Titel 'Nutzung von hochsensitiven C-reaktiven Protein-Tests in der primären und sekundären ASCVD-Prävention' umfasst Kooperationen mit Atropos Health und der Wake Forest University School of Medicine. Das zweite Poster, 'Wirkung der IL-6-Inhibition auf die Lipoprotein(a)-Spiegel: Eine systematische Übersicht und Meta-Analyse', ist eine gemeinsame Anstrengung mit der Wake Forest University School of Medicine und einem unabhängigen Forscher aus Toronto.
Diese Präsentationen verdeutlichen den Fokus von Tourmaline Bio auf die Entwicklung transformierender Medikamente für Patienten mit lebensverändernden immunologischen und entzündlichen Erkrankungen.
- Tourmaline Bio will present two posters at a major industry conference, demonstrating ongoing research efforts
- The company is collaborating with respected institutions like Wake Forest University School of Medicine, potentially enhancing research credibility
- None.
NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that it expects to present two posters at the upcoming 19th Annual Cardiometabolic Health Congress (CMHC), taking place October 17-19, 2024, in Boston, MA.
These posters highlight Tourmaline's ongoing commitment to further characterizing inflammatory cardiovascular risk, as well as potential therapeutic mechanisms of IL-6 inhibition.
Poster Presentations:
Title: Utilization of High-Sensitivity C-Reactive Protein Testing in Primary and Secondary ASCVD Prevention
Authors: Emil deGoma, MD1; Yung Chyung, MD1; John Walsh, MD1; C. William Pike, MD2; Jananee Muralidharan, MD2; Vincent Marino2; J. Craig Davis2; Saurabh Gombar, MD, PhD2; Michael D. Shapiro, DO, MCR3
Affiliations:
1Tourmaline Bio, Inc., New York, NY, USA
2Atropos Health, Inc., New York, NY, USA
3Wake Forest University School of Medicine, Winston-Salem, NC, USA
Title: Effect of IL-6 Inhibition on Lipoprotein(a) Levels: A Systematic Review and Meta-Analysis
Authors: Saeid Mirzai, DO1; Emil deGoma, MD2; John Walsh, MD2; Raya Mahbuba, MSc3; Yung Chyung, MD2; Michael D. Shapiro, DO, MCR1
Affiliations:
1Wake Forest University School of Medicine, Winston-Salem, NC, USA
2Tourmaline Bio, Inc., New York, NY, USA
3Independent researcher, Toronto, ON, Canada
For more information, please visit https://www.cardiometabolichealth.org/19th-annual-cmhc/.
About Tourmaline Bio
Tourmaline is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases. Tourmaline’s lead asset is pacibekitug (also referred to as TOUR006).
About Pacibekitug
Pacibekitug (also referred to as TOUR006) is a long-acting, fully-human, anti-IL-6 monoclonal antibody with best-in-class potential and differentiated properties including a naturally long half-life, low immunogenicity, and high binding affinity to IL-6. Pacibekitug has been previously studied in approximately 450 participants, including patients with autoimmune disorders, across six completed clinical trials. Tourmaline is developing pacibekitug in thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD) as its first two indications, with additional diseases under consideration.
For more information about Tourmaline Bio and pacibekitug, please visit https://www.tourmalinebio.com.
Media Contact
Scient PR
Sarah Mishek
SMishek@ScientPR.com
Investor Contact
Meru Advisors
Lee M. Stern
lstern@meruadvisors.com
FAQ
What is Tourmaline Bio (TRML) presenting at the 2024 Cardiometabolic Health Congress?
When and where is the 2024 Cardiometabolic Health Congress that Tourmaline Bio (TRML) is attending?
What areas of research do Tourmaline Bio's (TRML) poster presentations focus on?
Who are Tourmaline Bio's (TRML) collaborators for the poster presentations at the 2024 CMHC?
